Infective endocarditis: Difference between revisions

From IDWiki
(: added strep and HACEK)
(: added MIC for streps)
Line 133: Line 133:
 
|
 
|
 
|-
 
|-
! colspan=5 | Viridans group ''Streptococcus'' or ''Streptococcus gallolyticus'' highly susceptible to [[penicillin]]
+
! colspan=5 | Viridans ''Streptococcus'' or ''Streptococcus gallolyticus'' highly susceptible to [[penicillin]] (MIC ≤0.12 μg/mL)
 
|-
 
|-
 
| NVE
 
| NVE
Line 181: Line 181:
 
| use if allergy
 
| use if allergy
 
|-
 
|-
! colspan=5 | Viridans group ''Streptococcus'' or ''Streptococcus gallolyticus'' relatively resistant to [[penicillin]]
+
! colspan=5 | Viridans ''Streptococcus'' or ''Streptococcus gallolyticus'' relatively resistant to [[penicillin]] (MIC >0.12 μg/mL)
 
|-
 
|-
 
| rowspan=2 | NVE
 
| rowspan=2 | NVE

Revision as of 20:59, 9 March 2020

Background

  • Infection of heart valves, either prosthetic or native

Organisms

Clinical Presentation

Management

  • Varies by causative organism and prosthetic vs. native valve
Indication Antibiotic Dose Duration Notes
MSSA and other oxacillin-susceptible Staphylococcus
NVE oxacillin 12 g/day IV in 4-6 doses 6 weeks can treat for 2 weeks in uncomplicated right-sided NVE
NVE cefazolin 6 g/day IV in 3 doses 6 weeks in patients with non-anaphylactoid penicillin allergy
PVE oxacillin, plus 12 g/day in 6 doses ≥6 weeks use cefazolin or vancomycin if allergy
rifampin, plus 900 mg/day IV/PO in 3 doses
gentamicin 3 mg/kg/day IV/IM in 2-3 doses 2 weeks
MRSA and other oxacillin-resistant Staphylococcus
NVE vancomycin 30 mg/kg/day IV in 2 doses 6 weeks target trough 10-20 μg/mL
NVE daptomycin ≥8 mg/kg/dose 6 weeks
PVE vancomycin, plus 30 mg/kg/day in 2 doses ≥6 weeks target vancomycin trough of 10-20 μg/mL
rifampin, plus 900 mg/day IV/PO in 3 doses
gentamicin 3 mg/kg/day IV/IM in 2-3 doses 2 weeks
Enterococcus susceptible to penicillin and gentamicin
NVE or PVE ampicillin, plus 2 g IV q4h 4-6 weeks 4 weeks if symptoms <3 months; 6 weeks if symptoms >3 months or if PVE
gentamicin 3 mg/kg IBW in 2-3 doses
NVE or PVE ampicillin, plus 2 g IV q4h 6 weeks alternative regimen if CrCl <50
ceftriaxone 2 g IV q12h
Enterococcus susceptible to penicillin and resistant to aminoglycosides
NVE or PVE ampicillin, plus 2 g IV q4h 6 weeks
ceftriaxone 2 g IV q12h
Enterococcus resistant to penicillin and susceptible to vancomycin and aminoglycosides
NVE or PVE vancomycin, plus 30 mg/kg/day IV in 2 doses 6 weeks
gentamicin 3 mg/kg/day IV/IM in 3 doses
Enterococcus resistant to penicillin, aminoglycosides, and vancomycin
NVE or PVE linezolid 600 mg IV/PO q12h >6 weeks
NVE or PVE daptomycin 10-12 mg/kg/dose >6 weeks
Viridans Streptococcus or Streptococcus gallolyticus highly susceptible to penicillin (MIC ≤0.12 μg/mL)
NVE crystalline penicillin G 12-18 MU/day IV in 4-6 doses 4 weeks
NVE ceftriaxone 2 g IV/IM q24h 4 weeks
NVE penicillin or ceftriaxone, plus as above 2 weeks
gentamicin 3 mg/kg IV/IM q24h
NVE vancomycin 30 mg/kg/day IV in 2 doses 4 weeks use if allergy, target 10-15 μg/mL
PVE crystalline penicillin G, or 24 MU/day IV in 4-6 doses 6 weeks
ceftriaxone, with or without 2 g IV/IM q24h
gentamicin 3 mg/kg IV/IM q24h 2 weeks
PVE vancomycin 30 mg/kg/day IV in 2 doses 6 weeks use if allergy
Viridans Streptococcus or Streptococcus gallolyticus relatively resistant to penicillin (MIC >0.12 μg/mL)
NVE crystalline penicillin G, plus 24 MU/day IV in 4-6 doses 4 weeks
gentamicin 3 mg/kg IV/IM q24h
NVE vancomycin 30 mg/kg/day IV in 2 doses 4 weeks use if allergy, target 10-15 μ/mL
PVE crystalline penicillin G, or 24 MU/day IV in 4-6 doses 6 weeks
ceftriaxone, plus 2 g IV/IM q24h
gentamicin 3 mg/kg IV/IM q24h
PVE vancomycin 30 mg/kg/day IV in 2 doses 6 weeks use if allergy
HACEK bacterium
NVE ceftriaxone 2 g IV/IM q24h 4 weeks
PVE ceftriaxone 2 g IV/IM q24h 6 weeks
NVE or PVE ciprofloxacin 1000 mg/day PO in 2 doses 6 weeks

References

  1. ^  Kasper Iversen, Nikolaj Ihlemann, Sabine U. Gill, Trine Madsen, Hanne Elming, Kaare T. Jensen, Niels E. Bruun, Dan E. Høfsten, Kurt Fursted, Jens J. Christensen, Martin Schultz, Christine F. Klein, Emil L. Fosbøll, Flemming Rosenvinge, Henrik C. Schønheyder, Lars Køber, Christian Torp-Pedersen, Jannik Helweg-Larsen, Niels Tønder, Claus Moser, Henning Bundgaard. Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis. New England Journal of Medicine. 2019;380(5):415-424. doi:10.1056/nejmoa1808312.
  2. ^  John A Wildenthal, Andrew Atkinson, Sophia Lewis, Sena Sayood, Nathanial S Nolan, Nicolo L Cabrera, Jonas Marschall, Michael J Durkin, Laura R Marks. Outcomes of Partial Oral Antibiotic Treatment for Complicated Staphylococcus aureus Bacteremia in People Who Inject Drugs. Clinical Infectious Diseases. 2022;76(3):487-496. doi:10.1093/cid/ciac714.
  3. ^  Sarah Freling, Noah Wald-Dickler, Josh Banerjee, Catherine P Canamar, Soodtida Tangpraphaphorn, Dara Bruce, Kusha Davar, Fernando Dominguez, Daniel Norwitz, Ganesh Krishnamurthi, Lilian Fung, Ashley Guanzon, Emi Minejima, Michael Spellberg, Catherine Spellberg, Rachel Baden, Paul Holtom, Brad Spellberg. Real-World Application of Oral Therapy for Infective Endocarditis: A Multicenter, Retrospective, Cohort Study. Clinical Infectious Diseases. 2023;77(5):672-679. doi:10.1093/cid/ciad119.